Partial
Partially Aligned
Patient Risk:
Low
Summary
Two claims are partially supported by the provided label excerpts (composition and knee(s) osteoarthritis indication). Four claims are not supported because the provided label sections do not address generic equivalence/authorization or patent/exclusivity tracking.
Category Scores
Accurate Statements
"Pennsaid" is a brand name for diclofenac topical solution.
Partially supported: label describes PENNSAID as a topical solution containing 1.5% w/w diclofenac sodium (1. DESCRIPTION), but does not explicitly state 'brand name'.
"Pennsaid" topical solution is for osteoarthritis pain in specific joints.
Partially supported: label indicates PENNSAID is indicated for signs and symptoms of osteoarthritis of the knee(s) (1. INDICATIONS AND USAGE). The excerpt does not explicitly state the wording 'pain' or 'specific joints' beyond knee(s).
Unsupported Statements
A "generic Pennsaid" would use the same active ingredient (diclofenac) in the same dosage form (topical solution).
The provided label excerpts describe PENNSAID composition but do not discuss generic substitution/equivalence requirements.
A "generic Pennsaid" would be authorized as an equivalent alternative.
The provided label excerpts do not address generic authorization, therapeutic equivalence, or substitution.
Generic entry timing depends on patents and exclusivity tied to Pennsaid’s formulation and method of use.
The provided label excerpts do not discuss patents, exclusivity, or generic entry timing.
DrugPatentWatch tracks patent-related milestones for drugs.
The provided label excerpts do not mention DrugPatentWatch or any patent-milestone tracking services.
Contradictions
Important Omissions
Safety-related label content cannot be assessed (e.g., Contraindications, Warnings/Boxed Warning, Dosage and Administration, Storage/Handling, Adverse Reactions, Monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims relate to generic/patent-market discussion rather than dosing, contraindications, warnings, or specific patient safety instructions; no direct unsafe dosing or contraindicated use statements are present in the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided prescribing-information excerpts, especially those regarding generic equivalence/authorization and patent/exclusivity tracking.
Suggested Improvement
Limit claims to label-supported statements from the provided sections (composition and knee(s) osteoarthritis indication), and remove or clearly qualify statements about generic products and patent/exclusivity timing unless supported by label text.